The short report, 'Analysis on the Infiltration Tactics Concerning China's Espionage Cases', released on Sunday noted that the number of people in Taiwan prosecuted for Chinese espionage rose ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Patients were given ...

Fatty infiltration of the pancreas (FIP) has been recognized for nearly a century, yet many aspects of this condition remain unclear. Regular literature reviews on the diagnosis, consequences, and ...

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Taipei [Taiwan], January 13 (ANI): Taiwan's National Security Bureau (NSB) has released an analysis of China's infiltration tactics, underscoring Beijing's attempts to recruit active service members ...

Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also being trialled in other cancers. James Catto, professor of urology at the University of Sheffield ...

Cancer treatment has seen significant advancements in recent years with the introduction of innovative therapies. AstraZeneca’s Imfinzi (durvalumab) has emerged as a key contributor in this evolution.